Alphatec (NASDAQ:ATEC) Shares Down 7.5% – Should You Sell?

23 Apr 2026, 18:54 by Scott Moore · The Cerbat Gem

Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report)’s stock price dropped 7.5% during mid-day trading on Tuesday . The stock traded as low as $10.80 and last traded at $10.6850. Approximately 1,110,021 shares traded hands during trading, a decline of 62% from the average daily volume of 2,900,649 shares. The stock had previously closed at $11.55.

Wall Street Analyst Weigh In

ATEC has been the subject of several recent research reports. TD Cowen reiterated a “buy” rating on shares of Alphatec in a report on Tuesday, January 27th. Stifel Nicolaus cut their target price on Alphatec from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Piper Sandler restated an “overweight” rating on shares of Alphatec in a report on Wednesday, February 25th. Barclays raised their target price on Alphatec from $23.00 to $27.00 and gave the company an “overweight” rating in a report on Wednesday, January 7th. Finally, Wells Fargo & Company upgraded Alphatec to a “strong-buy” rating in a report on Wednesday, March 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alphatec currently has a consensus rating of “Moderate Buy” and an average target price of $22.82.

Check Out Our Latest Stock Report on Alphatec

Alphatec Trading Down 3.9%

The company has a fifty day simple moving average of $12.19 and a two-hundred day simple moving average of $16.11. The company has a debt-to-equity ratio of 40.35, a current ratio of 2.06 and a quick ratio of 1.28. The company has a market capitalization of $1.55 billion, a P/E ratio of -10.75 and a beta of 1.12.

Alphatec (NASDAQ:ATEC – Get Free Report) last posted its earnings results on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $212.93 million for the quarter, compared to the consensus estimate of $212.67 million. Alphatec’s quarterly revenue was up 20.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.23) earnings per share. On average, analysts forecast that Alphatec Holdings, Inc. will post -0.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Craig E. Hunsaker sold 82,765 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $12.45, for a total value of $1,030,424.25. Following the sale, the executive vice president directly owned 1,726,209 shares of the company’s stock, valued at approximately $21,491,302.05. This trade represents a 4.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Tyson Eliot Marshall sold 88,835 shares of the firm’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $12.49, for a total value of $1,109,549.15. Following the completion of the sale, the general counsel directly owned 559,459 shares in the company, valued at approximately $6,987,642.91. This represents a 13.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 726,972 shares of company stock valued at $9,184,386. 20.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alphatec

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Creative Planning grew its position in shares of Alphatec by 0.9% in the third quarter. Creative Planning now owns 58,654 shares of the medical technology company’s stock valued at $853,000 after purchasing an additional 534 shares during the last quarter. Valeo Financial Advisors LLC grew its position in shares of Alphatec by 2.1% in the third quarter. Valeo Financial Advisors LLC now owns 41,296 shares of the medical technology company’s stock valued at $600,000 after purchasing an additional 846 shares during the last quarter. Norden Group LLC grew its position in shares of Alphatec by 2.6% in the third quarter. Norden Group LLC now owns 36,676 shares of the medical technology company’s stock valued at $533,000 after purchasing an additional 939 shares during the last quarter. Arizona State Retirement System grew its position in shares of Alphatec by 2.8% in the third quarter. Arizona State Retirement System now owns 34,603 shares of the medical technology company’s stock valued at $503,000 after purchasing an additional 949 shares during the last quarter. Finally, Great Lakes Advisors LLC grew its position in Alphatec by 0.4% during the fourth quarter. Great Lakes Advisors LLC now owns 278,717 shares of the medical technology company’s stock worth $5,864,000 after buying an additional 1,226 shares in the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

About Alphatec

(Get Free Report)

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.